Blood test may spare some breast cancer patients from chemotherapy
NCT ID NCT07366112
First seen Jan 28, 2026 · Last updated May 13, 2026 · Updated 12 times
Summary
This study tests a personalized approach for women with hormone receptor-positive, HER2-negative early breast cancer. Doctors use a blood test (ctDNA) to see if the cancer responds to a combination of targeted pills (CDK4/6 inhibitors) and hormone therapy before surgery. If the blood test shows the cancer is gone, patients may avoid chemotherapy afterward. The goal is to reduce unnecessary treatment while keeping cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.